For pharmaceutical companies conducting HCP consent collection campaigns, one of the biggest challenges is often reaching the healthcare professional in the first place. A surgeon may spend most of the day in operating theatres, a hospital consultant’s calls may be managed by a departmental secretary, and a specialist working across several hospitals may not have a publicly available direct telephone number.
In such situations, the first person an outreach agent speaks to is frequently a medical secretary, personal assistant, practice manager or hospital administrator. These individuals can be instrumental in helping pharmaceutical companies reach otherwise inaccessible healthcare professionals, but their involvement raises an important question: can they provide consent on behalf of the doctor, or can they only help facilitate the process?
The distinction between direct vs indirect HCP consent collection has implications beyond the immediate outreach conversation. It affects how consent is obtained, what constitutes an acceptable response, how the outcome is documented and whether the resulting consent can be relied upon.
For pharmaceutical companies operating across multiple countries, these considerations become more complex because local regulations, healthcare practices and the authority of administrative representatives may differ.
Direct vs Indirect HCP Consent Collection: What’s the Difference?
Direct HCP consent collection involves obtaining the consent decision personally from the healthcare professional. The HCP receives information about the pharmaceutical company, the purpose of the communication, how their personal data will be used and the channels through which they may be contacted. They then provide their decision through an approved mechanism, such as a telephone conversation, electronic consent form or documented written confirmation.
This generally creates a clearer connection between the individual and the consent decision, although the consent must still meet the applicable legal requirements.
Indirect HCP consent, on the other hand, involves a third party participating in the process. That person may help establish contact with the doctor, forward a consent request, communicate a decision already made by the HCP or, where legally permissible, act as an authorized representative.
The difficulty is that these situations can sound remarkably similar during an outreach conversation.
A secretary who agrees to forward a consent request is facilitating communication. A secretary who says the doctor has already agreed is reporting a decision that may need verification. A secretary who claims authority to consent on the doctor’s behalf is acting as a representative, and that authority must be established before the response can be accepted.
For pharmaceutical companies, distinguishing between these interactions is essential to maintaining reliable consent records.
Can Medical Secretaries and Assistants Legally Provide HCP Consent?
Medical secretaries and assistants often manage almost every aspect of a physician’s professional correspondence. They screen calls, arrange appointments, coordinate meetings with pharmaceutical representatives and handle incoming emails. In some practices, external organizations rarely communicate with the doctor without first going through an assistant.
However, responsibility for managing communication does not automatically include authority to make personal consent decisions on the doctor’s behalf.
Under the GDPR framework, where consent is relied upon, it must be freely given, specific, informed and indicated through an unambiguous affirmative action. Organizations must also be able to demonstrate that valid consent was obtained.
A representative may be able to act on an individual’s behalf in certain circumstances, but the organization must establish that the person has legally sufficient authority and that the underlying consent requirements are satisfied.
Consider a physician who has authorized an assistant to manage professional email correspondence. That authorization does not necessarily extend to opting the doctor into ongoing pharmaceutical marketing communications. Even where representative authority exists, it may be limited to particular purposes, organizations or communication channels.
The same distinction applies to hospital administrators and practice managers. An administrator may be authorized to approve communications sent to a hospital department, but that does not automatically establish personal consent from every doctor working there.
For GDPR-compliant HCP consent, the relevant question is therefore not simply who manages the doctor’s correspondence, but who is entitled to make the particular consent decision and whether that authority can be demonstrated.
What Happens in Real HCP Consent Outreach?
The practical importance of this distinction becomes clearer when considering the conversations that arise during healthcare professional consent collection.
A medical secretary may tell an outreach agent that the consultant is unavailable but offer to forward the consent request. This is useful progress because the agent has established a route through which the HCP can receive the information. However, the interaction should be recorded as a forwarded request rather than consent obtained. The doctor still needs to provide the required decision through an approved mechanism.
Another common situation arises when an assistant says that the doctor regularly receives scientific updates from pharmaceutical companies and would be happy to receive further information. Although this sounds encouraging, it does not necessarily establish that the physician has agreed to receive communications from the particular company, for the specified purposes and through the proposed channels. The assistant may simply be describing the doctor’s usual communication preferences.
The situation becomes more complicated when a practice manager offers to provide consent for several doctors in the same clinic. Accepting those responses may appear efficient, particularly in large campaigns, but it raises questions about whether each physician has authorized the manager to make such decisions and whether that authority extends to the proposed communications.
These examples illustrate why HCP consent compliance cannot be reduced to a standard calling script. Outreach agents need to understand the difference between a helpful administrative interaction, a reported decision and a consent response that can legitimately be accepted.
Why Gatekeepers Matter Even When Direct Consent Is Required
Administrative staff can play a valuable role in HCP consent collection without being authorized to provide consent themselves.
A medical secretary may know when a consultant is available, whether a physician has moved to another hospital or which professional email address should be used for correspondence. For specialists whose schedules make direct contact particularly difficult, this information can be more useful than repeated unsuccessful calls.
There are also practical challenges that become apparent only when outreach begins. A large teaching hospital may have dozens of physicians associated with the same departmental telephone number. If agents treat each HCP record independently, the same receptionist may receive repeated calls from the same campaign, even after explaining when particular doctors can be reached.
Identifying shared contact numbers and retaining relevant administrative information can help avoid duplicated effort and improve subsequent outreach.
Medical specialty is another consideration. Surgeons, anesthesiologists and intensive care physicians may be difficult to reach during conventional calling hours, while doctors working primarily in outpatient clinics may have more predictable schedules. A secretary who helps arrange an appropriate callback can therefore contribute significantly to the eventual consent outcome.
This is particularly relevant to multilingual HCP consent collection, where the role of administrative staff and accepted communication practices may vary between healthcare systems. Understanding these differences requires more than translating a script; it requires familiarity with how healthcare professionals and their support teams communicate in each market.
The objective is not to bypass the HCP but to establish a practical route to obtaining their decision.
How HCP E-Consent Collection Can Bridge the Gap
Electronic consent can be particularly useful when an assistant or administrator is willing to help but the HCP is difficult to reach directly.
For example, a medical secretary may agree to forward an approved consent request to the physician’s professional email address, provided that the initial communication is permitted under the applicable rules. The doctor can then review the information and complete the consent form personally at a convenient time.
This allows administrative staff to facilitate the process while preserving a direct decision from the healthcare professional.
HCP e-consent collection can also make it easier to maintain structured evidence of the decision, including the date, consent wording, communication preferences and relevant HCP identifier.
However, sending an electronic consent request does not itself constitute consent. The process must establish an appropriate basis for the initial contact, adequately identify the consenting individual and capture a valid decision.
For pharmaceutical companies managing large HCP populations, combining human outreach with approved electronic consent mechanisms can offer a practical alternative to repeated direct calling attempts.
Why Country-Specific Compliance Rules Matter
Pharmaceutical companies conducting consent campaigns across multiple markets cannot assume that the same requirements apply everywhere.
GDPR principles are relevant across the European Economic Area, but national rules governing electronic marketing, professional communications and call recording may differ. Other countries have their own privacy and communication frameworks, while individual pharmaceutical companies may impose additional compliance requirements.
Before outreach begins, the company’s legal and compliance teams need to establish what constitutes acceptable consent in each market. This includes whether verbal consent can be accepted, whether electronic confirmation is required, whether representative-provided consent is permissible and what evidence of authority must be retained.
These decisions then need to be translated into practical instructions for outreach agents. Someone speaking with a medical secretary should know whether the response can be accepted, whether direct confirmation is necessary or whether the interaction requires further compliance review.
It is also important to distinguish the lawful basis for processing personal data from the rules governing particular communication channels. Not every lawful HCP communication necessarily requires GDPR consent, and obtaining consent under one framework does not automatically satisfy every applicable electronic marketing requirement.
For international pharmaceutical consent management programs, consistency is important, but so is the ability to accommodate legitimate differences between markets.
Why Consent Status Classification and Documentation Matter
One of the most easily overlooked aspects of large HCP consent campaigns is how individual outreach outcomes are classified.
A database may have a simple field marked “consent obtained” or “consent not obtained,” but actual conversations rarely fall into such neat categories.
A secretary may have agreed to forward the request, an HCP may have asked for a callback, or an electronic consent form may have been delivered but not completed. In another case, a representative may have communicated a positive decision that still requires verification.
All these interactions represent different stages of the process, and treating them as equivalent can distort campaign results.
Consider two HCP records. In the first, a secretary has agreed to forward the consent request. In the second, the doctor has personally completed an approved electronic consent form. Both interactions represent progress, but only the second establishes a completed direct consent action, assuming the applicable requirements have been satisfied.
If both are classified as successful consents, the reported HCP consent response rates become misleading.
A reliable workflow should therefore distinguish between verified consent, consent pending confirmation, requests forwarded, callbacks scheduled, representative authority under review and consent declined or withdrawn.
This classification also helps identify where outreach is encountering difficulties. A high number of forwarded requests with few completed consents may indicate a problem with follow-up. Repeated callbacks that never result in direct contact may suggest that calling schedules or administrative coordination need to change.
Accurate HCP consent documentation is equally important. Consent records should establish who provided the decision, when it was made, what information was presented and which purposes and communication channels were covered. Where a representative is involved, the organization may also need evidence of that person’s authority.
These practices are an important part of effective HCP consent management and broader pharmaceutical consent management, helping companies maintain reliable records and distinguish operational progress from consent that can legitimately be used.
How LiveSalesman Supports Direct and Indirect HCP Consent Collection
At LiveSalesman, we recognize that successful HCP consent outreach depends on much more than contacting names on a database. The accessibility of healthcare professionals, the role of medical secretaries, the quality of contact information and local communication practices all influence how a campaign progresses.
Our HCP consent collection services support pharmaceutical and healthcare organizations through multilingual, multichannel outreach across international markets. Rather than treating every contact attempt as an isolated interaction, our approach takes account of the practical barriers that can prevent outreach teams from reaching healthcare professionals.
Medical secretaries, practice managers and hospital administrators are often essential to overcoming these barriers. Engaging with them appropriately can help establish contact routes, coordinate follow-ups and facilitate delivery of consent requests without confusing administrative assistance with authority to provide consent.
Where permitted by the client’s approved compliance framework, telephone outreach can also be combined with electronic consent mechanisms, allowing healthcare professionals to review and complete requests personally.
Equally important is how campaign outcomes are recorded. Distinguishing between administrative engagement, pending responses and verified consent provides pharmaceutical companies with a more accurate understanding of their consent coverage and the challenges affecting campaign performance.
For organizations considering HCP consent collection outsourcing, this operational understanding matters. The value of a specialist outreach partner lies not simply in increasing contact volumes, but in helping pharmaceutical companies navigate the practical complexities of reaching HCPs while supporting consistent documentation and compliance processes.
Final Thoughts: Making HCP Consent Collection Work in Practice
Direct consent generally provides the clearest connection between the healthcare professional and the decision, but obtaining it is not always straightforward. In many healthcare environments, administrative staff control access to physicians, and overlooking their role can make consent campaigns unnecessarily difficult.
The answer is not to treat every helpful response from a secretary or administrator as consent. It is to recognize the difference between facilitating communication and making a decision on someone else’s behalf, and to design outreach processes around that distinction.
By combining appropriate gatekeeper engagement with direct HCP confirmation wherever possible, pharmaceutical companies can improve access to difficult-to-reach professionals without weakening the reliability of their consent records. Where representative-provided consent is legally permissible, establishing and documenting the representative’s authority remains essential.
Ultimately, effective consent collection is about more than the number of positive responses recorded. It is about ensuring that the permissions collected are valid, properly documented and suitable for the communications they are intended to support.
Looking to improve HCP consent coverage across multiple markets?
LiveSalesman helps pharmaceutical and healthcare organizations manage the practical challenges of reaching healthcare professionals through multilingual outreach, administrative coordination and approved consent collection workflows.
Explore LiveSalesman’s HCP Consent Collection and Management Services.
Comments are closed.